^
Association details:
| Biomarker: | MET amplification |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | unecritinib (TQ-B3101) (ALK inhibitor, ROS1 inhibitor, c-MET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A phase I study to evaluate safety, tolerability, pharmacokinetics, and preliminary antitumor activity of TQ-B3101
Published date:
05/28/2020
Excerpt:
Tumor response was evaluated in 24 pts with ALK+/ROS1+/MET amplification….TQ-B3101 was well tolerated and showed preliminary antitumor activity in ALK+, ROS1+ and MET amplification pts.
DOI:
10.1200/JCO.2020.38.15_suppl.e21705
Trial ID:
